Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II individualized irinotecan dosing in FOLFIRI based on UGT1A1 polymorphism for first-line metastatic colorectal cancer
2013-001275-21Phase 2Completed
- Sponsor
- Centre Jean Perrin
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in metastatic colorectal adenocarcinoma (mCRC), sponsored by Centre Jean Perrin. Primary endpoint: Severe hematologic and gastrointestinal toxicities. Started Jun 2013; status: completed.
02
Drugs
irinotecan
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2013-001275-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001275-21.